XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
The company has raised US$4.5 million in funding for its AI operating system
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Lack of technology transfer stands out as a formidable barrier
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
With the establishment of five different precious metals alloy powder production methods
Subscribe To Our Newsletter & Stay Updated
